The NCPE considers ramucirumab not to be cost effective as either combination therapy with paclitaxel or as monotherapy, and therefore cannot recommend this drug for reimbursement at the submitted price.
The NCPE considers scaubitril/valsartan (Entresto) a cost-effective treatment for adult patients with symptomatic chronic heart failure with reduced ejection fraction. Therefore reimbursement is recommended.
The NCPE does not recommend the reimbursement of lumacaftor + ivacaftor (Orkambi) for cystic fibrosis patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene at the submitted price. Patients on Managed Access Programme will continue on Orkambi
Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.
The NCPE does not recommend reimbursement of Apremilast (Otezla®) for psoriatic arthritis at the submitted price.
The NCPE does not recommend reimbursement of Ataluren (Translarna®).
Reimbursement not Recommended at the Submitted Price.
The NCPE does not recommend reimbursement Nivolumab (Opdivio®) at the submitted price.
The NCPE does not recommend reimbursement of nivolumab (Opdivo®) at the submitted price.
The NCPE does not recommend reimbursement of Nintedanib (Ofev®) at the submitted price.